Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): committee papers A
Table of contents
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the company - AbbVie
03 - NICE request to the company for clarification on their submission
04 – Company clarification response
05 - Consultee submission – The Hepatitis C Trust
06 – Consultee submission – Liver 4 Life
07 – Clinical expert submission – Millson
08 – Clinical expert submission - Kulasegaram
|
Hepatitis C (chronic) - ombitasvir/paritaprevir/ritonavir (with or without dasabuvir): committee papers A
29 July 2015 (7.45 Mb 2 sec) |
This page was last updated: 29 July 2015